Attachment 2- Sole Source Justification.pdf

CUI

SOURCE SELECTION INFORMATION – SEE 2.101 AND 3.104

DEFENSE LOGISTICS AGENCY

DLA CONTRACTING SERVICES OFFICE - PHILADELPHIA

700 ROBBINS AVENUE

PHILADELPHIA, PENNSYLVANIA 19111-5092

JUSTIFICATION

FOR OTHER THAN FULL AND OPEN COMPETITION

Upon the basis of the following justification, I hereby approve the issuance of the contractual action described below using other than full and open competition, pursuant to the authority cited herein.

1. IDENTIFICATION OF THE AGENCY AND CONTRACTING ACTIVITY

Agency Activity Defense Logistics Agency (DLA) Medical Directorate 700 Robbins Avenue Philadelphia, PA 19111

Contracting Activity DLA Contracting Services Office – Philadelphia Site 700 Robbins Avenue Philadelphia, PA 19111

Controlled by: DLA DCSO Philadelphia CUI Category: General Procurement and Acquisition / Source Selection Information see FAR 2.101 & 3.104 Distribution/Dissemination Controls: FED ONLY

Justification and Approval for Other than Full and Open Competition

Curvo-BroadJump Medical Subscription

CUI

SOURCE SELECTION INFORMATION – SEE 2.101 AND 3.104

2. NATURE AND/OR DESCRIPTION OF THE ACTION BEING APPROVED.

Pursuant to 10 U.S.C. 3204(a)(1) and Federal Acquisition Regulation (FAR) part 6.103-1(d) where the highly specialized brand name servicesfor this requirement. This justification details the authority to acquire services on an other than full and open basis and seeks approval to execute a brand name acquisition, restricted to Curvo-BroadJump, as they are the only responsible source. ;

there are no other re-sellers of Curvo-BroadJump able to provide the service for this brand name product due to the proprietary nature of a license agreement for commercial sales data for all medical/surgical and pharmaceutical products for use by the DLA Troop Support Medical Directorate. Use of this brand name description in the acquisition is essential to the Government’s requirements, thereby precluding consideration of a product of another company. No other brand name for all pharmaceutical and medical/surgical product is compatible with brand name “Curvo- BroadJump” a license agreement for commercial sales data. Only “Curvo-BroadJump” Software will support the required licenses to be owned by DLA. The resultant solicitation will be issued to acquire a license agreement for commercial sales data for all medical/surgical and pharmaceutical products for use by the DLA Troop Support Medical Directorate in support of US Department of War (DoW) medical materiel purchasing programs and planning applications. This requirement seeks to acquire a license agreement for commercial sales data, collected on a weekly basis for all pharmaceutical and medical/surgical product pricing.

The Government contemplates award of a Firm-Fixed-Price (FFP) contract for performance during a twelve (12) month base period and two (2) 12-month option periods, where the total period of performance will consist of thirty-six (36) months, if all options are exercised. Curvo-BroadJump is the only technically capable, responsible source for the license agreement, and, more specifically, its sales data and pricing algorithm, which compiles weekly sales data and trend analysis of pharmaceutical and medical spend. The Government’s requested Period of Performance (POP) is detailed as follows:

Base Year 07/30/26 – 07/29/27 Option Year 1 07/30/27 – 07/29/28 Option Year 2 07/30/28 – 07/29/29

3. A DESCRIPTION OF THE SUPPLIES OR SERVICES REQUIRED TO MEET THE

AGENCY’S NEEDS (INCLUDING THE ESTIMATED VALUE)

The DLA Troop Support Medical Directorate – pproximately upport cost, quality, and compliance assessments across medical materiel programs.

Curvo-BroadJump Medical Subscription

CUI

SOURCE SELECTION INFORMATION – SEE 2.101 AND 3.104

a site license for up to 19 users. PharmaChecker provides pricing transparency across all GPOs and allows comparison of pharmaceutical pricing by account type, class of trade, and DSH eligibility.

The tool supplies contextual market insights that are essential for understanding pricing variances and supporting DLA’s medical procurement planning.

anticipated start date of June 30, 2026, is . This acquisition is conducted under 10 and open competition and therefore requires justification and approval under FAR 6.104. No providing the proprietary commercial sales data and analytics required. Market research confirms that no authorized resellers or equivalent products can meet the Government’s needs.

4. IDENTIFICATION OF THE STATUTORY AUTHORITY PERMITTING OTHER

THAN FULL AND OPEN COMPETITION.

description, which prevents full and open competition and therefore must be justified and approved in accordance with FAR 6.104. This restriction does not apply to descriptions, as those allow full and open competition; however, no “equal” product exists for this that is unique to a single manufacturer. There are no authorized resellers capable of providing the Government’s needs.

pricing data required for this subscription. Award to any other source would result in unacceptable duplication of effort and cost, including reprogramming labor and higher subscription expenses, essential to meet the Government’s requirements.

5. A DEMONSTRATION THAT THE PROPOSED CONTRACTOR’S UNIQUE

QUALIFICATIONS OR THE NATURE OF THE ACQUISITION REQUIRES USING

THE AUTHORITY CITED.

Curvo-BroadJump Medical Subscription

The nature of this requirement for DLA’s Curvo-BroadJump license agreement for medical and pharmaceutical sales data necessitates the use of the authority cited herein.

The only known source that offers for sale a product that compiles commercial medical/surgical and pharmaceutical sales data, distributed on a weekly basis is Curvo-BroadJump. Curvo-BroadJump tracks nearly 40% of the U.S. healthcare market’s nonlabor spend, creating a trusted source of market intelligence, formatted in a manner that addresses the customer’s specific data analytics requirement(s). Curvo-BroadJump’s data collection enables fair, fact-based decisions that help providers measure, manage and optimize cost, quality and compliance. The license agreement also provides access to Curvo-BroadJump’s PharmaChecker application via a site license for up to 19 users. PharmaChecker brings pricing transparency to pharmaceuticals utilizing neutral, unbiased data across all GPOs and allows comparison of drug pricing respective of account type, class of trade and DSH eligibility. PharmaChecker gives users further contextual information and insights into the market to help better understand specific pricing.

DLA Troop Support uses the components of the DMLSS to support customers in the “best value” selection of medical supplies. The medical treatment facilities use DMLSS data daily for selection of products and for regional standardization decisions. In addition, DoW Services’ medical planners and logisticians, as well as the DLA Troop Support Medical Directorate, use the sales data to ascertain the availability and support of pharmaceutical products on the commercial marketplace.

Product trend analysis can be applied to determine whether the Services’ healthcare requirements is supported by average healthcare industry/market pricing and industry common practices. Curvo- BroadJump data will serve as a key component of the various DMLSS systems to identify, track, and quantify which products are available in the commercial marketplace.

Alternative products available on the commercial market that were evaluated and determined not to be fully comparable are offerings from sources as follows:

1. ECRI: (www.ecri.org) PriceGuide™ The product offered by ECRI provides valuable benchmarking data; it does not, however, satisfy the more comprehensive requirement by the Readiness Division for rolling 24-month commercial sales data collected monthly and reported quarterly, both at the retail and wholesale levels, for both pharmaceutical and medical/surgical products, along with product synonym files and packaging information. The ECRI Price Guide does not meet the Government’s current requirement for readiness support of critical functionalities.

2. Global Healthcare Exchange, LLC (GHX) (https://www.ghx.com) The GHX Data service provides several valuable components of Pharmaceutical/Medical Surgical data; it does not, however, offer visibility and insight into what medical materiel are being sold in the commercial side of the medical healthcare industry, nor does it gather all pharmaceutical and medical/surgical commercial sales data available. As a result, the GHX data feed does not meet the Government’s current requirement.

3. IQVIA (https://iqvia.com)

IQVIA data is delivered quarterly. Since it is used in the DMLSS-W applications; it does not have the same level of data coverage on pharm data that Broadjump has to meet Medical’s needs.

6. A DESCRIPTION OF EFFORTS MADE TO ENSURE THAT OFFERS ARE

SOLICITED FROM AS MANY POTENTIAL SOURCES AS POSSIBLE, INCLUDING

WHETHER A NOTICE WAS OR WILL BE PUBLICIZED AS REQUIRED BY PART 5

AND, IF NOT, WHICH EXCEPTION UNDER PART 5 APPLIES.

In accordance with FAR 5.201(b)(1), a synopsis will be posted to SAM.gov to provide all commercial entities with an opportunity to submit proposals for this requirement.

7. A DETERMINATION BY THE CONTRACTING OFFICER THAT THE

ANTICIPATED COST TO THE GOVERNMENT WILL BE FAIR AND REASONABLE

As the Contracting Officer, I hereby determine that the anticipated cost to the Government will be

1. The Government will conduct a thorough price analysis using appropriate techniques for commercial data subscription services. The analysis will include, but will not be limited to, the following methods: (1) Comparison to previously paid prices for similar medical/surgical and pharmaceutical commercial sales data procured for

)(ii)). (2) Comparison to competitive published

(3) Comparison to pricing identified through market research for the same or similar commercial data subscriptions

(4) Comparison to historical pricing from Government and

(5) Comparison to the (6) negotiated price is fair and reasonable and reflects prudent acquisition practices. The determination will be documented in the contract file in accordance with applicable policy and regulation.

8. THE MARKET RESEARCH CONDUCTED (SEE PART 10) AND THE RESULTS

OR A STATEMENT OF THE REASON MARKET RESEARCH WAS NOT

CONDUCTED.

Market research techniques included a review of acquisition history for contracts used by the directorate to procure similar services and a search of Contract Opportunities and GSA websites for other vendors with similar data service offerings. Primary comparative factors used to analyze alternatives included technical service offerings, and functional familiarity, to the DLA Medical Directorate.

Alternative subscription services considered included products offered by ECRI Price Guide, IQVIA, as well as the Global Health Exchange (GHX) Product Data Feed.

Results of market research, inclusive of an analysis of the Curvo-BroadJump solution, are detailed as follows:

IQVIA (https://iqvia.com) Explain what IQVIA provides and what it can’t provide that Curvo-BroadJump can.

IQVIA data is delivered quarterly and as it is used in the DMLSS-W applications, it does not have the same level of data coverage on pharm data that Broadjump has to meet Medical’s needs.

ECRI: (www.ecri.org) PriceGuide™

The product offered by ECRI provides valuable benchmarking data, it does not satisfy the more comprehensive requirement by the Readiness Division for rolling 24-month commercial sales data collected monthly and reported quarterly, both at the retail and wholesale levels, for both pharmaceutical and medical/surgical products, along with product synonym files and packaging information. The ECRI Price Guide does not meet the Government’s current requirement for readiness support of critical functionalities.

Global Healthcare Exchange, LLC (GHX) (https://www.ghx.com) The GHX Data service provides several valuable components of Pharmaceutical/Medical Surgical data, it does not offer visibility and insight into what medical materiel are being sold in the commercial side of the medical healthcare industry, nor does it gather all pharmaceutical and medical/surgical commercial sales data available. As a result, the GHX data feed was determined to not meet the Government’s current requirement,

9. ANY OTHER FACTS SUPPORTING THE USE OF OTHER THAN FULL AND OPEN

COMPETITION

N/A

10. LISTING OF THE SOURCES, IF ANY, THAT EXPRESSED AN INTEREST IN THE

ACQUISITION IN WRITING.

Curvo-BroadJump

11. A STATEMENT OF THE ACTIONS, IF ANY, THE AGENCY MAY TAKE TO

REMOVE OR OVERCOME ANY BARRIERS TO COMPETITION BEFORE ANY

SUBSEQUENT ACQUISITION FOR THE SUPPLIES OR SERVICES REQUIRED.

At this time, Curvo-BroadJump medical and pharmaceutical data license is the only service provider on the market that can fulfill this requirement and meet the Government’s needs. However, DLA continues to exercise competition as often as possible and is required to conduct ongoing reviews to keep abreast of new technology, both in industry and the Government. As a continuing effort, DLA utilizes a variety of vendors, manufacturers, and contracts to fulfill its requirements and will continue the practice of surveying the market to ensure full and open competition to the maximum extent practicable.

12. CONTRACTING OFFICER CERTIFICATION THAT THE JUSTIFICATION IS

ACCURATE AND COMPLETE TO THE BEST OF THE CONTRACTING OFFICER’S

KNOWLEDGE AND BELIEF.

Requirements/Technical Certification

Pursuant to FAR 6.104(b), I hereby certify that the data provided for which I am responsible, and which form a basis for this justification is complete and accurate to the best of my knowledge and

Program Support Manager Defense Medical Logistics Standard Support-Wholesale (DMLSS-W) Troop Support Medical Directorate

Contracting Officer’s Certification and Approval

Pursuant to FAR 6.104(a)(12) and FAR 6.104-2(a), I hereby certify that this justification is accurate and complete to the best of my knowledge and belief.

Contracting Officer DLA Contracting Services Office – Philadelphia